ZA202213322B - Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting - Google Patents
Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targetingInfo
- Publication number
- ZA202213322B ZA202213322B ZA2022/13322A ZA202213322A ZA202213322B ZA 202213322 B ZA202213322 B ZA 202213322B ZA 2022/13322 A ZA2022/13322 A ZA 2022/13322A ZA 202213322 A ZA202213322 A ZA 202213322A ZA 202213322 B ZA202213322 B ZA 202213322B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- microenvironment
- overcoming
- compositions
- mediated resistance
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940075628 hypomethylating agent Drugs 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 229940123546 E-selectin antagonist Drugs 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038856P | 2020-06-14 | 2020-06-14 | |
| US202063060605P | 2020-08-03 | 2020-08-03 | |
| US202063198856P | 2020-11-17 | 2020-11-17 | |
| PCT/US2021/036992 WO2021257398A1 (en) | 2020-06-14 | 2021-06-11 | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202213322B true ZA202213322B (en) | 2024-04-24 |
Family
ID=76731129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/13322A ZA202213322B (en) | 2020-06-14 | 2022-12-08 | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230218649A1 (enExample) |
| EP (1) | EP4164655A1 (enExample) |
| JP (1) | JP2023529485A (enExample) |
| KR (1) | KR20230024402A (enExample) |
| CN (1) | CN116033907A (enExample) |
| AU (1) | AU2021292458A1 (enExample) |
| BR (1) | BR112022025480A2 (enExample) |
| CA (1) | CA3181278A1 (enExample) |
| IL (1) | IL298977A (enExample) |
| MX (1) | MX2022015894A (enExample) |
| WO (1) | WO2021257398A1 (enExample) |
| ZA (1) | ZA202213322B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250100273A (ko) * | 2023-12-26 | 2025-07-03 | 서울대학교병원 | 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2264043T3 (pl) | 2005-09-02 | 2018-04-30 | Glycomimetics, Inc. | Heterobifunkcyjne inhibitory pan-selektyny |
| WO2009073911A1 (en) | 2007-12-10 | 2009-06-18 | Mater Medical Research Institute | Treatment and prophylaxis |
| CA2760292A1 (en) | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| KR102055958B1 (ko) * | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
| WO2015048616A1 (en) * | 2013-09-30 | 2015-04-02 | Glycomimetics, Inc. | Methods and compositions for treating and/or preventing mucositis |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| US20200171005A9 (en) | 2015-12-02 | 2020-06-04 | Glycomimetics, Inc. | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker |
| AU2017341065B2 (en) | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
| JP7275131B2 (ja) * | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| KR20200128025A (ko) * | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2020219419A1 (en) | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Multimeric pan–selectin antagonists |
| JP2022529806A (ja) | 2019-04-24 | 2022-06-24 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 |
| US20220265691A1 (en) | 2019-07-12 | 2022-08-25 | Glycomimetics, Inc. | Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types |
-
2021
- 2021-06-11 AU AU2021292458A patent/AU2021292458A1/en not_active Abandoned
- 2021-06-11 CA CA3181278A patent/CA3181278A1/en active Pending
- 2021-06-11 US US18/001,614 patent/US20230218649A1/en active Pending
- 2021-06-11 IL IL298977A patent/IL298977A/en unknown
- 2021-06-11 WO PCT/US2021/036992 patent/WO2021257398A1/en not_active Ceased
- 2021-06-11 CN CN202180056345.7A patent/CN116033907A/zh active Pending
- 2021-06-11 KR KR1020237001653A patent/KR20230024402A/ko active Pending
- 2021-06-11 MX MX2022015894A patent/MX2022015894A/es unknown
- 2021-06-11 JP JP2022576447A patent/JP2023529485A/ja active Pending
- 2021-06-11 EP EP21736926.3A patent/EP4164655A1/en active Pending
- 2021-06-11 BR BR112022025480A patent/BR112022025480A2/pt not_active Application Discontinuation
-
2022
- 2022-12-08 ZA ZA2022/13322A patent/ZA202213322B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021257398A1 (en) | 2021-12-23 |
| CN116033907A (zh) | 2023-04-28 |
| CA3181278A1 (en) | 2021-12-23 |
| EP4164655A1 (en) | 2023-04-19 |
| BR112022025480A2 (pt) | 2023-01-17 |
| MX2022015894A (es) | 2023-01-24 |
| KR20230024402A (ko) | 2023-02-20 |
| AU2021292458A1 (en) | 2023-01-19 |
| US20230218649A1 (en) | 2023-07-13 |
| IL298977A (en) | 2023-02-01 |
| JP2023529485A (ja) | 2023-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| WO2020191326A8 (en) | Treatment of acute myeloid leukemia (aml) with venetoclax failure | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| BR112012009250A2 (pt) | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma | |
| TW201613589A (en) | Combination methods for treating cancers | |
| PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| MX2019009726A (es) | Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados. | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| MX2023014131A (es) | Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo. | |
| ZA202213322B (en) | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| CO2025008528A2 (es) | Anticuerpo anti-cmet, conjugado anticuerpo-fármaco y método de preparación de estos y uso de estos | |
| NZ801252A (en) | Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2024006168A (es) | Composicion farmaceutica y uso de la misma. | |
| MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. | |
| EP4706653A3 (en) | Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| NZ760040A (en) | Methods of treating brain tumors using combination therapy | |
| MX2023005314A (es) | Composiciones de nanoparticulas para tratamiento de cancer. |